THERAFLU COLD & SORE THROAT HOT LIQUID OTC
Generic Name and Formulations:
Acetaminophen 325mg, pheniramine maleate 20mg, phenylephrine HCl 10mg; pwd packets; natural lemon flavor; contains sodium 44mg per packet.
Novartis Consumer Health
Indications for THERAFLU COLD & SORE THROAT HOT LIQUID:
Nasal congestion, rhinorrhea, sore throat, fever, headache, minor aches and pains.
Dissolve contents of 1 packet into 8oz hot water; sip while hot. Consume entire drink within 10–15mins. Take every 4 hours; max 6 packets/24hrs.
During or within 14 days of MAOIs. Concomitant other acetaminophen products.
Hepatic dysfunction. Cardiovascular disease. Hypertension. Thyroid disease. Diabetes. GI or GU obstruction. Glaucoma. Asthma. Lower respiratory disorders. Sodium restricted diet. Discontinue if symptoms worsen or persist after 2–7 days. Pregnancy. Nursing mothers.
Analgesic + antihistamine + sympathomimetic.
See Contraindications. Hypertensive crisis with MAOIs. Increased risk of hepatotoxicity with ≥3 alcoholic drinks/day; avoid. β-blockers may increase the pressor effects of sympathomimetics. Antihypertensives antagonized. Increased CNS effects with other CNS depressants.
Drowsiness, anticholinergic effects, nervousness, dizziness, insomnia, excitability in children, hepatotoxicity (overdosage).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC